摘要
目的:分析司美格鲁肽联合二甲双胍治疗超重或肥胖2型糖尿病的临床效果。方法:将2022年6月—2024年2月常熟市梅李人民医院收治的70例超重或肥胖2型糖尿病患者随机分为两组。对照组35例,采用度拉糖肽治疗;观察组35例,采用司美格鲁肽联合二甲双胍治疗。比较两组疗效。结果:观察组治疗总有效率高于对照组(P=0.040)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。治疗后,两组空腹血糖、餐后2 h血糖、总胆固醇水平及体质量、体质量指数降低,且观察组低于对照组(P<0.05)。结论:司美格鲁肽联合二甲双胍治疗超重或肥胖2型糖尿病的临床效果良好,可改善患者血糖、血脂水平,降低体质量、体质量指数水平,且能够保证治疗安全性。
Objective:To analyze the clinical effect of semaglutide combined with metformin in treatment of overweight or obesity with type 2 diabetes mellitus.Methods:From June 2022 to February 2024,70 overweight or obese type 2 diabetes patients admitted to Meili People's Hospital in Changshu were randomly divided into two groups.The control group consisted of 35 patients and was treated with dulaglutide;the observation group also had 35 patients and was treated with semaglutide combined with metformin.The efficacy of the two groups was compared.Results:The overall response rate of treatment in the observation group was higher than that in the control group(P=0.040).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the levels of fasting blood glucose,2 h postprandial blood glucose,total cholesterol and the body weight,body mass index in the two groups decreased,and the levels in the observation group were lower than those in the control group(P<0.05).Conclusion:Semaglutide combined with metformin has a good clinical effect in the treatment of overweight or obesity with type 2 diabetes mellitus,and can improve the blood glucose and blood lipid levels,reduce the body weight and body mass index,and ensure the safety of treatment.
作者
王晓霞
Wang Xiaoxia(Department of Internal Medicine,Meili People's Hospital in Changshu City,Changshu 215500,Jiangsu Province,China)
出处
《中国社区医师》
2025年第31期40-42,共3页
Chinese Community Doctors
